Hyperlipidemias are frequently associated with and are considered an important cause of
erectile dysfunction in men. This association has been attributed to the impairment of blood
flow through endothelium-dependent relaxation in smooth muscle cells of corpus cavernosum.
Basic science and human research suggest that the vascular pathophysiology of male and female
sexual dysfunction may be similar, as the first phase of the female sexual response is
mediated by a combination of vasocongestive and neuro-muscular event which include increased
clitoral length and diameter, as well as increased vaginal lubrication, wall engorgement and
luminal diameter. The investigators have shown that women with hyperlipidemia had a higher
prevalence of sexual dysfunction as compared with age-matched women without hyperlipidemia.
The aim of this study was to asses the effect of anti-hyperlipidemic drugs (fenofibrate and
rosuvastatin, single or in combination) on validated indices of sexual function in
hyperlipidemic men and women with sexual dysfunction at baseline.